Odell Dean, MD
Urology · Monroe, LANPI 1073656765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,444 of the $7,186 with a category attached, or 61.8%. 31 manufacturers reported payments, led by Axonics, Inc. at 37.1% of the total. Reporting peaked in 2023 at $2,244 and has fallen 79.5% since, to $460 in 2025.
Across 240 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Astellas Pharma US Inc$1K
- Coloplast$513
- Johnson & Johnson$461
- Endo Pharmaceuticals Inc.$448
- Urovant Sciences Inc$253
- plus $2K from 25 others
What the payments were for
- Travel & lodging$2,08529%
- Food & beverage$4,44462%
- Education$6579%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 23 | $2,669 |
| Astellas Pharma US Inc | 46 | $1,100 |
| Coloplast | 14 | $513 |
| Johnson & Johnson(2 entities) | 22 | $461 |
| Endo Pharmaceuticals Inc. | 37 | $448 |
| Urovant Sciences Inc | 13 | $253 |
| Pfizer | 9 | $219 |
| Endo USA, Inc. | 10 | $168 |
| Sumitomo Pharma America, Inc. | 9 | $162 |
| AbbVie(2 entities) | 7 | $132 |
| Bayer | 7 | $125 |
| Antares Pharma, Inc. | 7 | $124 |
| Tolmar, Inc. | 5 | $100 |
| Smith+Nephew | 1 | $98 |
| Urogen Pharma, Inc. | 3 | $80 |
| Rochester Medical Corporation | 3 | $70 |
| Teleflex LLC | 4 | $68 |
| Boston Scientific | 2 | $47 |
| Progenics Pharmaceuticals, Inc. | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $41 |
| Hollister Incorporated | 2 | $40 |
| ABC Home Medical Supply, Inc. | 2 | $36 |
| Neotract Inc. | 2 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Telix Pharmaceuticals | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| 180 Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,186 in reported general payments places this provider in the 75th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 12 | $177,697 |
| MyrbetriqMirabegron | 169 | $87,825 |
| GemtesaVibegron | 17 | $9,982 |
| Tamsulosin Hcl | 741 | $9,166 |
| Abiraterone Acetate | 11 | $8,789 |
| Testosterone | 46 | $7,120 |
| Mirabegron ErMirabegron | 20 | $6,324 |
| Finasteride | 373 | $5,806 |
| Solifenacin Succinate | 159 | $3,623 |
| Trimethoprim | 46 | $3,509 |
| Oxybutynin Chloride ErOxybutynin Chloride | 144 | $3,052 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $2,326 |
| Potassium Citrate ErPotassium Citrate | 36 | $2,175 |
| Silodosin | 25 | $1,885 |
| Trospium Chloride | 16 | $1,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $461 | $177,69712 claims |
| Astellas Pharma US IncMyrbetriq | $1,100 | $87,825169 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $162 | $9,98217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 199 urology providers in Louisiana.
Other urology in Monroe
- Paul MurphyMonroe$11K
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Sunil PurohitCovington$99K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Kevin HebertShreveport$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.